Federal
Register Notices > Notice of
Application 2006 >
Mallinckrodt Inc.
FR Doc E6-8917 [Federal Register: June 8, 2006 (Volume 71, Number 110)]
[Notices] [Page 33315] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr08jn06-75]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations
(CFR), this is notice that on December 12, 2005, Mallinckrodt Inc., 3600 North
Second Street, St. Louis, Missouri 63147, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of
the basic classes of controlled substances listed in Schedules I and II:
Drug
|
Schedule
|
Codeine-N-oxide (9053)
|
I
|
Difenoxin (9168)
|
I
|
Dihydromorphine (9145)
|
I
|
Morphine-N-oxide (9307)
|
I
|
Norlevorphanol (9634)
|
I
|
Normorphine (9313)
|
I
|
Tetrahydrocannabinols (7370)
|
I
|
Alfentanil (9737)
|
II
|
Amphetamine (1100)
|
II
|
Ecgonine (9180)
|
II
|
Codeine (9050)
|
II
|
Dextropropoxyphene, bulk (9273)
|
II
|
Dihydrocodeine (9120)
|
II
|
Diphenoxylate (9170)
|
II
|
Diprenorphine (9058)
|
II
|
Etorphine HCL (9059)
|
II
|
Fentanyl (9801)
|
II
|
Hydrocodone (9193)
|
II
|
Hydromorphone (9150)
|
II
|
Levo-alphacetylmethadol (9648)
|
II
|
Levorphanol (9220)
|
II
|
Meperidine (9230)
|
II
|
Methadone (9250)
|
II
|
Methadone intermediate (9254)
|
II
|
Methamphetamine (1105)
|
II
|
Methylphenidate (1724)
|
II
|
Metopon (9260)
|
II
|
Morphine (9300)
|
II
|
Nabilone (7379)
|
II
|
Opium extracts (9610)
|
II
|
Opium fluid extract (9620)
|
II
|
Opium tincture (9630)
|
II
|
Opium, granulated (9640)
|
II
|
Opium, powdered (9639)
|
II
|
Oxycodone (9143)
|
II
|
Oxymorphone (9652)
|
II
|
Phenazocine (9715)
|
II
|
Remifentanil (9739)
|
II
|
Sufentanil (9740)
|
II
|
Thebaine (9333)
|
II
|
The firm plans to manufacture the listed controlled substances for internal
use and for sale to other companies.
Any other such applicant and any person who is presently registered with DEA
to manufacture such a substance may file comments or objections to the issuance
of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail may be
addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, Washington, DC 20537,
Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL);
or any being sent via express mail should be sent to DEA Headquarters,
Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis
Highway, Alexandria, Virginia 22301; and must be filed no later than August 7,
2006.
Dated: June 1, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-8917 Filed 6-7-06; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|